Voriconazole

Histoplasmosis, Candidemia, Coccidioidomycosis + 24 more
Treatment
13 FDA approvals
20 Active Studies for Voriconazole

What is Voriconazole

VoriconazoleThe Generic name of this drug
Treatment SummaryVoriconazole is an antifungal medication used to treat serious fungal infections in immunocompromised people. It is used to treat invasive candidiasis, invasive aspergillosis, and other emerging fungal infections. Voriconazole is also effective against some fungi that are resistant to other antifungal medications. It was approved by the FDA in 2002 under the trade name Vfend.
Voriconazoleis the brand name
image of different drug pills on a surface
Voriconazole Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Voriconazole
Voriconazole
2002
85

Approved as Treatment by the FDA

Voriconazole, also known as Voriconazole, is approved by the FDA for 13 uses like Esophageal Candidiasis and Scedosporium Infection .
Esophageal Candidiasis
Scedosporium Infection
Systemic candidiasis
refractory Fungal Infections
Invasive Aspergillosis
Hematopoietic stem cells
Neutropenia
Neuroaspergillosis
Candida (fungus)
prophylaxis of moderate Pneumocystis pneumonia
Candidemia
Fusariosis
Mycoses

Effectiveness

How Voriconazole Affects PatientsVoriconazole is a medication used to stop fungus from growing. It can cause liver and sun sensitivity issues in some people.
How Voriconazole works in the bodyVoriconazole is a medication used to treat fungal infections caused by organisms such as _Aspergillus spp._ and _Candida spp_. Voriconazole works by blocking a key enzyme called 14-alpha sterol demethylase. This enzyme is necessary for fungi to produce a type of fat called ergosterol, which is essential for cell membrane function. By blocking the production of ergosterol, voriconazole limits fungal cell growth and allows the body's immune system to clear the infection.

When to interrupt dosage

The proposed dosage of Voriconazole is contingent upon the diagnosed condition, including Esophageal Candidiasis, Meningitis, Fungal and Immunosuppression. The degree of measure varies as per the procedure of delivery (e.g. Tablet or Oral) outlined in the table below.
Condition
Dosage
Administration
talaromycosis
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Aspergillosis
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Meningitis, Fungal
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Aspergillosis
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
prophylaxis of moderate Pneumocystis pneumonia
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Peritonitis
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Debridement
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Lung Transplant
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Hematopoietic stem cells
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Candidemia
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Fusariosis
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Aspergillosis
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Histoplasmosis
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Coccidioidomycosis
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Neutropenia
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Immunosuppression
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Esophageal Candidiasis
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Yeast Infection
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
Candida (fungus)
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal
aspergillus endophthalmitis
10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL
, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Warnings

Voriconazole Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Voriconazole may interact with Pulse Frequency
There are 20 known major drug interactions with Voriconazole.
Common Voriconazole Drug Interactions
Drug Name
Risk Level
Description
(R)-warfarin
Major
The metabolism of (R)-warfarin can be decreased when combined with Voriconazole.
(S)-Warfarin
Major
The metabolism of (S)-Warfarin can be decreased when combined with Voriconazole.
1,2-Benzodiazepine
Major
The metabolism of 1,2-Benzodiazepine can be decreased when combined with Voriconazole.
3,5-diiodothyropropionic acid
Major
The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Voriconazole.
5-androstenedione
Major
The metabolism of 5-androstenedione can be decreased when combined with Voriconazole.
Voriconazole Toxicity & Overdose RiskOverdosing on Voriconazole can cause sensitivity to light and a lengthened QT interval. If someone overdoses, it is recommended to provide supportive care and monitor their heart activity. Activated charcoal can help remove unabsorbed drug from the body, and hemodialysis can be used to remove absorbed drug at a rate of 121 mL/min. Studies have found that taking high doses of Voriconazole can lead to liver cancer in rats and mice.
image of a doctor in a lab doing drug, clinical research

Voriconazole Novel Uses: Which Conditions Have a Clinical Trial Featuring Voriconazole?

31 active clinical trials are currently underway to investigate the potential of Voriconazole to address Aspergillosis, Aspergillosis and Penicillium marneffei infection.
Condition
Clinical Trials
Trial Phases
talaromycosis
0 Actively Recruiting
Esophageal Candidiasis
0 Actively Recruiting
Osteomyelitis
0 Actively Recruiting
Fusariosis
0 Actively Recruiting
Neutropenia
5 Actively Recruiting
Phase 1, Phase 2, Phase 4, Phase 3
Immunosuppression
10 Actively Recruiting
Phase 2, Phase 4, Not Applicable, Phase 3, Early Phase 1
Aspergillosis
0 Actively Recruiting
Candida (fungus)
0 Actively Recruiting
Histoplasmosis
0 Actively Recruiting
Mycoses
0 Actively Recruiting
Aspergillosis
0 Actively Recruiting
Neuroaspergillosis
0 Actively Recruiting
refractory Oral Candidiasis
0 Actively Recruiting
Lung Transplant
17 Actively Recruiting
Not Applicable, Phase 2, Phase 3, Phase 1
Candidemia
4 Actively Recruiting
Phase 3, Phase 2
Peritonitis
0 Actively Recruiting
Meningitis, Fungal
0 Actively Recruiting
Debridement
0 Actively Recruiting
Yeast Infection
0 Actively Recruiting
Valve Replacement
0 Actively Recruiting

Voriconazole Reviews: What are patients saying about Voriconazole?

5Patient Review
10/29/2014
Voriconazole for Aggressive Fungal Infection - Invasive Aspergillosis
I'm very photosensitive, so this summer I made sure to get a good tan. Even with that protection, I still can't seem to get my dosage high enough to where it's therapeutic. I'm also working on shrinking a fungal infection in my lungs.
5Patient Review
4/2/2019
Voriconazole for A Fungal Infection - Aspergillosis
Voriconazole has been a lifesaver for me. I'm 60 now and it's kept the fungal infection at bay for years. Recently, I've also started to get skin cancer on my face and ears. So, during the summer months, I have to make sure to wear a wide-brimmed hat when I go outside.
4.7Patient Review
12/20/2011
Voriconazole for Aggressive Fungal Infection - Invasive Aspergillosis
I saw significant improvements in my asthma symptoms after just one week of using this medication. I was struggling for two years before they found the root cause (fungus in my lungs) but now I feel like a normal person again.
3Patient Review
11/11/2022
Voriconazole for Fungal Infection of the Esophagus
I used this treatment for thirteen days to treat a stubborn candida infection. I lost half of my hair during that time, and I'm still losing it one month later. There were also some vision-related side effects, but they're gone now. The candida symptoms returned two days after stopping the treatment. Although the vaginal yeast feels a little bit better, it's still painful and tests positive.
2.7Patient Review
5/4/2012
Voriconazole for Aggressive Fungal Infection - Invasive Aspergillosis
V-fend has been successful in treating my ABPA, but I have developed more severe allergic reactions each time. This last reaction could have been fatal if I hadn't stopped taking the medication.
2.3Patient Review
9/18/2010
Voriconazole for Aggressive Fungal Infection - Invasive Aspergillosis
I had some really intense hallucinations while on this medication. I was also extremely irritable and saw things that weren't actually there. It was a scary experience for both me and the people around me.
2.3Patient Review
2/5/2012
Voriconazole for Aggressive Fungal Infection - Invasive Aspergillosis
I have been having severe gastrointestinal issues since taking this medication. My joints and muscles hurt, and now my face, throat, and stomach are swelling severely . I look like I've gained a lot of weight in a short amount of time.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about voriconazole

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is voriconazole an antibiotic?

"Voriconazole is used to treat fungal infections. It stops the growth of fungi."

Answered by AI

How long do you take voriconazole?

"The length of time that you will have to take Vfend (voriconazole) will vary depending on the severity of your infection. Some people may need to take this medication for several months."

Answered by AI

Which is better fluconazole or voriconazole?

"At the end of the study, the researchers found that voriconazole was just as good as fluconazole at treating esophageal candidiasis."

Answered by AI

What are the side effects of voriconazole?

"The most commonly reported side effects of voriconazole are blurred vision, changes in vision color, visual disturbance, and enhanced visual perception. Other side effects include fever, nausea, skin rash, vomiting, and chills."

Answered by AI

Clinical Trials for Voriconazole

Image of Johns Hopkins University School of Medicine in Baltimore, United States.

Fostamatinib for Lung Transplant Rejection

18 - 99
All Sexes
Baltimore, MD
Background: People who have lung transplants often survive 6 or 7 years. But some people develop donor-specific antibodies (DSA) after their transplants; antibodies are proteins that attack foreign invaders in the body. Antibodies typically kill viruses and other agents that can cause disease. But when the antibodies attack a transplanted organ, they can cause the body to reject the new tissues. People who develop DSA after a transplant have a higher risk of death within 1 year. Objective: To test a drug called fostamatinib in people who develop DSA after a lung transplant. Eligibility: Adults aged 18 and older who developed DSA after a lung transplant. Design: Participants will continue with their standard care after a transplant. Fostamatinib is a pill taken by mouth. Some participants will take the study drug along with their standard care; others will take a placebo. A placebo is a pill that looks just like the real drug but contains no medicine. All participants will take 1 pill per day for 2 weeks. Then they will take 2 pills per day for the next 6 weeks. Participants will have clinic visits every 2 weeks while taking their pills. They will have a physical exam, with blood and urine tests, during each visit. If participants have fluid samples collected from their airways during their standard treatment, some extra fluid may be collected for this study. Participants will have a follow-up visit 4 weeks after they stop taking their pills.
Phase 1
Waitlist Available
Johns Hopkins University School of Medicine (+4 Sites)Sean T Agbor-Enoh, M.D.
Have you considered Voriconazole clinical trials? We made a collection of clinical trials featuring Voriconazole, we think they might fit your search criteria.Go to Trials
Image of Kidney Transplant Research in Vancouver, Canada.

Immunosuppressants for Kidney Transplant

18+
All Sexes
Vancouver, Canada
Kidney transplant is often the best treatment for people with kidney failure, but transplanted kidneys don't always last a lifetime. Many transplanted kidneys fail within 12 years, leaving patients needing dialysis or another transplant. One major issue is something called "allosensitization," which happens when the immune system attacks the donated kidney due to foreign markers on the kidney. This makes it harder to match a patient with another donor kidney in the future. To try to prevent this, patients are given immunosuppressants (drugs that weaken the immune system) after a transplant to stop the immune system from attacking the new kidney. However, after a kidney transplant fails and patients return to dialysis, there's no clear evidence that continuing immunosuppressants helps prevent allosensitization. Plus, these drugs have serious risks, including infections, heart disease, and even cancer. The PART study is a pilot study designed to explore whether continuing immunosuppression after a failed transplant for two years (instead of stopping after six months) can lower the risk of allosensitization and whether it is safe to do so. This pilot will also gather data that will be used for a larger trial in the future. The study will be done at 12 different research centers, and around 96 patients will be enrolled in the pilot trial. The ultimate goal is to better understand if continuing immunosuppressants after transplant failure can make a difference, and whether it's safe enough to proceed to a larger, more definitive trial.
Waitlist Available
Has No Placebo
Kidney Transplant Research
Image of Weill Cornell Medical College in New York, United States.

Luspatercept for Clonal Cytopenia

18+
All Sexes
New York, NY
The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include: * How many patients experience improvements in their low blood counts (red cells, platelets, or white cells) within 24 weeks, based on specific criteria for blood conditions like myelodysplastic syndromes (MDS)? * How long these improvements last before the condition worsens or changes. * The percentage of participants showing improvements at 12, 24, and 48 weeks. * How long it takes for the condition to progress to more severe diseases like myeloid disorders. * How long red blood cell responses last and how quickly these responses are seen. * The average change in hemoglobin levels over 24 weeks. * How many patients need blood transfusions during the study and how soon transfusions are required. * Changes in participants' well-being and energy levels based on a standardized questionnaire. * Monitoring for any side effects, including progression to MDS or leukemia, heart-related issues, or sudden increases in hemoglobin. Participants will: * Receive luspatercept as an injection every three weeks. * Visit the clinic every three weeks for treatment and monitoring.
Phase 2
Recruiting
Weill Cornell Medical CollegePinkal Desai, MDBristol-Myers Squibb
Have you considered Voriconazole clinical trials? We made a collection of clinical trials featuring Voriconazole, we think they might fit your search criteria.Go to Trials
Image of University of California, Los Angeles (Site #: 71123) in Los Angeles, United States.

Belumosudil for Lung Transplant

Any Age
All Sexes
Los Angeles, CA
The purpose of this study is to see if taking the study drug, Belumosudil, for 52 weeks in addition to your usual care and medication, will prevent Chronic Lung Allograft Dysfunction (CLAD) in participants who have a lung biopsy that shows evidence of rejection or inflammation to the transplanted lung(s). For this study, biopsies that show evidence of Acute Rejection (AR), Lymphocytic Bronchiolitis (LB), Organizing Pneumonia (OP) or Acute Lung Injury (ALI) are referred to as "Qualifying Biopsies"; patients who had evidence of one or more of these conditions on a recent biopsy are eligible for enrollment in this study. Belumosudil is an investigational drug that blocks a molecule in the body that reduces inflammation and scarring and may play a role in the development and progression of CLAD. Belumosudil is a drug approved by the FDA to treat adults and children 12 years and older with chronic graft-versus-host disease (cGVHD), a condition with some similarities to CLAD. The primary objective it to determine the efficacy of treatment with Belumosudil + maintenance immunosuppression (IS) versus placebo + maintenance IS on preventing the subsequent development of probable or definite CLAD, lung retransplant, or death.
Phase 2
Recruiting
University of California, Los Angeles (Site #: 71123) (+11 Sites)Scott M. Palmer, M.D., M.H.S.
Image of NYU Langone Health in New York, United States.

New Protocol for Lung Transplants

18+
All Sexes
New York, NY
The study team developed an uncontrolled donation after circulatory death (uDCD) protocol that preserves lungs for just over 3 hours after death using positive end expiratory pressure (PEEP) and supplemental oxygen. The study will assess lung uDCD program safety by continuous review of operations/clinical records from each case activation and transplantation. Attrition outcomes include rates of initial and continued lung preservation, donation authorization, lung recovery, passing ex-vivo lung perfusion (EVLP) performance testing, and lung transplantation. Planned viability assessments also include macroscopic determination, radiology (X-ray), and fiber optic bronchoscopy before initiating EVLP. We expect \~50% of lungs assessed with EVLP will be transplanted to meet sustainability targets. Safety outcomes include the primary outcome, primary graft dysfunction (PGD) grade III at 72 hours, and secondarily survival one year after transplantation.
Recruiting
Has No Placebo
NYU Langone HealthStephen Wall, MD
Image of Ronald Reagan UCLA Medical Center, Department of Anesthesiology & Perioperative Medicine in Los Angeles, United States.

TEE Techniques for Swallowing Difficulty After Lung Transplant

18+
All Sexes
Los Angeles, CA
The primary outcome of this study is dysphagia (difficulty swallowing) on postoperative speech and swallow evaluation following lung transplantation. Transesophageal echocardiography (TEE) (creates pictures of the heart from inside the participants body) is routinely performed for all lung transplantations at the University of California, Los Angeles (UCLA) and it is the standard of care. Patients are randomized to two groups. The intervention group would limit the number of TEE clips (# pictures taken) per case. The control group would leave the number of TEE clips to the discretion of the attending anesthesiologist. The investigators hypothesize that reduction in TEE imaging during lung transplantation will reduce dysphagia.
Recruiting
Has No Placebo
Ronald Reagan UCLA Medical Center, Department of Anesthesiology & Perioperative MedicineJ.Prince Neelankavil, MD
Have you considered Voriconazole clinical trials? We made a collection of clinical trials featuring Voriconazole, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security